BackArmata Pharmaceuticals Overview

Armata Pharmaceuticals Total Liabilities

Track Armata Pharmaceuticals's total liabilities ($320M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$321.12M
113.66% YoYΔ $170.83M vs prior year quarter

Peer trimmed avg / median

Loading

Armata Pharmaceuticals Total Liabilities History

Loading

Armata Pharmaceuticals vs. peers: Total Liabilities Comparison

Loading

Armata Pharmaceuticals Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Armata Pharmaceuticals (ARMP) FAQ

Armata Pharmaceuticals (ARMP) currently reports a total liabilities of $320M as of June 2026. That compares with $150M in the prior-year period — up 113.7% year over year. Use the charts on this page to explore Armata Pharmaceuticals's total liabilities history and peer comparisons.

Armata Pharmaceuticals's total liabilities increased from $150M to $320M — a 113.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Armata Pharmaceuticals reported $320M in total liabilities as of June 2026. That compares with $150M in the prior-year period — up 113.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $320M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Armata Pharmaceuticals, and consider following ARMP for alerts when major investors trade the stock.

Armata Pharmaceuticals is classified in the Healthcare sector. On total liabilities, it currently shows $320M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ARMP with unrelated industries.